Table 1.

Summary of adverse events and serious adverse events of infection

	Placebo (N = 3,876), n (%)	Denosumab (N = 3,886), n (%)	P value
Adverse events of infections	2,108 (54.4)	2,055 (52.9)	0.1721
Serious adverse events of infection	133 (3.4)	159 (4.1)	0.1399
Serious opportunistic infection	3 (<0.1)	4 (0.1)	0.7130
AEs of infection leading to study discontinuation	4 (0.1)	3 (<0.1)	0.6979
Fatal infections	6 (0.2)	6 (0.2)	0.9787